-
AND PREVALENCE OF CANCER AND RARE DISORDERS
-
INCREASING APPROVAL FOR GENE THERAPY PRODUCTS
- FAVOURABLE GOVERNMENT SUPPORT FOR GENE THERAPY
-
RESTRAINTS
- CLINICAL TRIAL FAILURE ASSOCIATED WITH GENE THERAPY
-
CHALLENGES ASSOCIATED WITH GENE THERAPY DELIVERY
-
OPPORTUNITY
-
GROWING INVESTMENT IN THE FIELD OF GENE THERAPY
-
ONGOING CLINICAL TRIALS
-
ASSOCIATED WITH GENE THERAPY
-
PORTER'S FIVE FORCES MODEL
- THREAT OF NEW ENTRANTS
- BARGAINING POWER OF SUPPLIERS
- THREAT OF SUBSTITUTES
- BARGAINING POWER OF BUYERS
- INTENSITY OF RIVALRY
-
IMPACT OF COVID-19 ON THE GLOBAL GENE THERAPY MARKET
-
GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE
-
OVERVIEW
-
VIRAL VECTOR
- LENTIVIRAL VECTORS (LVVS)
- RETROVIRUS VECTORS
- ADENOVIRAL VECTORS (ADVS)
- ADENO-ASSOCIATED VIRAL VECTORS (AAVS)
-
NON-VIRAL VECTOR
- PHYSICAL VECTOR
- CHEMICAL VECTOR
-
THERAPY MARKET, BY GENE TYPE
-
OVERVIEW
-
ANTIGEN
-
CYTOKINE
-
TUMOR SUPPRESSOR
-
SUICIDE
-
DEFICIENCY
-
GROWTH FACTORS
-
RECEPTORS
-
OTHERS
-
OVERVIEW
-
ONCOLOGICAL DISORDERS
-
RARE DISEASES
-
CARDIOVASCULAR DISEASES
-
NEUROLOGICAL DISORDERS
-
INFECTIOUS DISEASES
-
OTHERS
-
OVERVIEW
-
IN VIVO GENE THERAPY
-
EX VIVO GENE THERAPY
-
OVERVIEW
-
NORTH AMERICA
- US
- CANADA
-
EUROPE
- GERMANY
- FRANCE
- UK
- ITALY
- SPAIN
- REST OF EUROPE
-
ASIA-PACIFIC
- CHINA
- INDIA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- REST OF ASIA-PACIFIC
-
REST OF THE WORLD
-
MIDDLE EAST & AFRICA
-
SOUTH AMERICA
-
INTRODUCTION
-
MARKET SHARE ANALYSIS, 2024
-
COMPETITOR DASHBOARD
-
PUBLIC PLAYERS STOCK SUMMARY
-
COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
-
KEY DEVELOPMENTS & GROWTH STRATEGIES
- PRODUCT APPROVAL/ PRODUCT LAUNCH
- ACQUISITION/ EXPANSION
- AGREEMENT/PARTNERSHIP/COLLABORATION
-
BRISTOL-MYERS SQUIBB COMPANY
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- SWOT ANALYSIS
- KEY STRATEGIES
-
LONZA
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCT OFFERED
- KEY DEVELOPMENTS
- SWOT ANALYSIS
- KEY STRATEGIES
-
UNIQURE N.V.
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- SWOT ANALYSIS
- KEY STRATEGIES
-
BLUEBIRD BIO, INC.
- COMPANY OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- KEY STRATEGIES
-
ORCHARD THERAPEUTICS PLC
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- KEY STRATEGIES
-
GENSIGHT BIOLOGICS
- COMPANY OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- KEY STRATEGIES
-
NOVARTIS AG
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- SWOT ANALYSIS
- KEY STRATEGIES
-
AMGEN INC.
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- SWOT ANALYSIS
- KEY STRATEGIES
-
SAREPTA THERAPEUTICS INC.
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCT OFFERED
- KEY DEVELOPMENTS
- KEY STRATEGIES
-
SPARK THERAPEUTICS, INC.
- COMPANY OVERVIEW
- FINANCIAL OVERVIEW
- PRODUCTS OFFERED
- KEY DEVELOPMENTS
- KEY STRATEGIES
-
DATA CITATIONS
-
BY REGION, 2019–2035 (USD BILLION) FOR RETROVIRUS VECTORS, BY REGION, 2019–2035 (USD BILLION) GENE THERAPY MARKET, FOR ADENOVIRAL VECTORS (ADVS), BY REGION, 2019–2035 (USD BILLION) (AAVS), BY REGION, 2019–2035 (USD BILLION) MARKET, FOR NON-VIRAL VECTOR, BY REGION, 2019–2035 (USD BILLION)
-
REGION, 2019–2035 (USD BILLION) FOR CHEMICAL VECTOR, BY REGION, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) GENE THERAPY MARKET, FOR ANTIGEN, BY REGION, 2019–2035 (USD BILLION)
-
BY REGION, 2019–2035 (USD BILLION) FOR GROWTH FACTORS, BY REGION, 2019–2035 (USD BILLION) GENE THERAPY MARKET, FOR RECEPTORS, BY REGION, 2019–2035 (USD BILLION) BILLION) (USD BILLION) BY REGION, 2019–2035 (USD BILLION) FOR RARE DISEASES, BY REGION, 2019–2035 (USD BILLION) GENE THERAPY MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2035 (USD BILLION) REGION, 2019–2035 (USD BILLION) FOR INFECTIOUS DISEASES, BY REGION, 2019–2035 (USD BILLION) GLOBAL GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION) BILLION) REGION, 2019–2035 (USD BILLION) FOR EX VIVO GENE THERAPY, BY REGION, 2019–2035 (USD BILLION) GLOBAL GENE THERAPY MARKET, BY REGION, 2019–2035 (USD BILLION)
-
TYPE, 2019–2035 (USD BILLION) FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION)
-
VECTOR, BY TYPE, 2019–2035 (USD BILLION) BY GENE TYPE, 2019–2035 (USD BILLION) BY APPLICATION, 2019–2035 (USD BILLION) BY DELIVERY METHOD, 2019–2035 (USD BILLION) MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
-
VECTOR, BY TYPE, 2019–2035 (USD BILLION) MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) MARKET, BY APPLICATION, 2019–2035 (USD BILLION) THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION) GERMANY: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
-
TYPE, 2019–2035 (USD BILLION) BY APPLICATION, 2019–2035 (USD BILLION) MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) FRANCE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) (USD BILLION) (USD BILLION) (USD BILLION) (USD BILLION) (USD BILLION) 2019–2035 (USD BILLION) VECTOR, BY TYPE, 2019–2035 (USD BILLION) BY GENE TYPE, 2019–2035 (USD BILLION) BY APPLICATION, 2019–2035 (USD BILLION) BY DELIVERY METHOD, 2019–2035 (USD BILLION) MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
-
VECTOR, BY TYPE, 2019–2035 (USD BILLION) MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) MARKET, BY APPLICATION, 2019–2035 (USD BILLION) THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION) REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) (USD BILLION) BY TYPE, 2019–2035 (USD BILLION) MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION) REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION) BILLION) 2019–2035 (USD BILLION) NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) ASIA-PACIFIC: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION) (USD BILLION) (USD BILLION) 2019–2035 (USD BILLION) VECTOR, BY TYPE, 2019–2035 (USD BILLION) MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) MARKET, BY APPLICATION, 2019–2035 (USD BILLION) THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION) INDIA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION)
-
TYPE, 2019–2035 (USD BILLION) APPLICATION, 2019–2035 (USD BILLION) BY DELIVERY METHOD, 2019–2035 (USD BILLION) MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
-
BY TYPE, 2019–2035 (USD BILLION) MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
-
TYPE, 2019–2035 (USD BILLION) FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) AUSTRALIA: GENE THERAPY MARKET, BY APPLICATION, 2019–2035 (USD BILLION) (USD BILLION) TYPE, 2019–2035 (USD BILLION) MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) REST OF ASIA-PACIFIC: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) TYPE, 2019–2035 (USD BILLION) MARKET, BY APPLICATION, 2019–2035 (USD BILLION) GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2035 (USD BILLION)
-
BY TYPE, 2019–2035 (USD BILLION) MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION)
-
METHOD, 2019–2035 (USD BILLION) THERAPY MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) EAST & AFRICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) NON-VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) & AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2035 (USD BILLION) (USD BILLION) METHOD, 2019–2035 (USD BILLION) MARKET, BY VECTOR TYPE, 2019–2035 (USD BILLION) GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2035 (USD BILLION) (USD BILLION) (USD BILLION) 2019–2035 (USD BILLION) BY DELIVERY METHOD, 2019–2035 (USD BILLION) STOCK SUMMARY EXPANSION SQUIBB COMPANY: PRODUCT OFFERED DEVELOPMENTS KEY DEVELOPMENTS
-
GENE THERAPY MARKET, GENE TYPE SEGMENT, 2024-2035 (USD BILLION) GENE THERAPY MARKET, BY GENE TYPE, 2024-2035 (USD BILLION) GENE THERAPY MARKET SHARE (%), BY GENE TYPE, 2024 MARKET, APPLICATION SEGMENT, 2024-2035 (USD BILLION) THERAPY MARKET, BY APPLICATION, 2024-2035 (USD BILLION) THERAPY MARKET SHARE (%), BY GENE TYPE, 2023 MARKET, DELIVERY METHOD SEGMENT, 2024-2035 (USD BILLION) THERAPY MARKET, BY DELIVERY METHOD, 2024-2035 (USD BILLION) GENE THERAPY MARKET SHARE (%), BY DELIVERY METHOD, 2023 THERAPY MARKET, BY REGION, 2024-2035 (USD BILLION) MARKET SHARE (%), BY REGION, 2023 GENE THERAPY MARKET, 2019-2035 BY COUNTRY, 2024-2035 (USD BILLION) SHARE (%), BY COUNTRY, 2024 MARKET, 2019-2035 (USD BILLION)
-
2023 (USD BILLION)
-
2024-2035 (USD BILLION)
-
BY COUNTRY, 2023 (%) MARKET, 2019-2035 (USD BILLION) SHARE, BY COUNTRY, 2024-2035 (USD BILLION) THERAPY MARKET SHARE, BY COUNTRY, 2024 (%) PLAYERS: COMPETITIVE ANALYSIS, 2024 GENE THERAPY MARKET SNAPSHOT
-
BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT SNAPSHOT OVERVIEW SNAPSHOT THERAPEUTICS INC.: FINANCIAL OVERVIEW SNAPSHOT
Leave a Comment